Clinical Pharmacology of Electronic Cigarettes   IRB#  15-15992  
 1  
Clinical Pharmacology of 
Electronic Cigarettes  
R01 DA039264 
UCSF IRB #: 15 -15992 
Clinical Trials.gov #: [STUDY_ID_REMOVED] 
Manual of Procedures (MOP)  
NEAL BENOWITZ, M.D. (PI)  
DELIA DEMPSEY, M.D. (CO -I) 
MACIEJ GONIEWICZ, Pharm.D., Ph.D. (CO-I)  
PEYTON JACOB, Ph.D. (CO-I)  
GIDEON ST. HELEN , Ph.D. (CO-I)  
KEVIN WALTON, Ph.D. (NIDA Study Officer)  
March  2018  

Clinical Pharmacology of Electronic Cigarettes   IRB#  15-15992  
 2 Table of Contents  
1 Table of Contents  
INVESTIGATORS, PERSONNEL, CONTACT INFORMATION ....................................................... 5 
BACKGROUND, GENERAL AIMS & STUDY DESIGN  ..................................................................... 6 
2 INTRODUCTION AND STUDY DESIGN  ................................................................................... 7 
2.1 RESEARCH QUESTION  ........................................................................................................... 7 
2.2 SPECIFIC AIMS  .......................................................................................................................... 8 
2.2.1  Specific Aim #1  ........................................................................................................................... 8 
2.2.2  Specific Aim #2  ........................................................................................................................... 8 
2.2.3  Specific Aim #3  ........................................................................................................................... 9 
3 STUDY DESIGN  .............................................................................................................................. 9 
3.1 DESIGN SUMMARY  ................................................................................................................. 9 
3.2 MAJOR STATISTICAL VARIABLES  ...................................................................................... 9 
3.3 PRIMARY RESEARCH SAMPLES  ........................................................................................ 10 
3.4 STUDY TIMELINE  ................................................................................................................... 10 
3.5 ELIGIBILITY  ............................................................................................................................. 10 
3.5.1  Inclusion Criteria  ...................................................................................................................... 11 
3.5.2  Exclusion Criteria  ..................................................................................................................... 11 
3.5.3  Eligibility Determination  ........................................................................................................ 13 
3.5.4  Reassessment of Eligibility  ..................................................................................................... 13 
3.54a  Outside Orientation Visit Window  .................................................................................. 13 
 3.54b  30 Days Past Screening Visit  ............................................................................................. 14 
4 IDs & Assignment  ......................................................................................................................... 14 
4.1.1  Study IDs  ................................................................................................................................... 14 
4.1.2  Assignment Procedure  ............................................................................................................ 15 
5 PARTICIPANT WITHDRAWAL  ................................................................................................ 16 
5.1.1  Dropout Definition  .................................................................................................................. 16 
5.1.2  Dropout Compensation  ........................................................................................................... 16 
Clinical Pharmacology of Electronic Cigarettes   IRB#  15-15992  
 3 5.1.3  Lost to Follow -Up .................................................................................................................... 17 
 5.13a  Contact Attempts  ................................................................................................................ 17 
 5.13b  Returning to Visit Procedures  .......................................................................................... 18 
6 VISIT SCHEDULE  ......................................................................................................................... 18 
6.1.1  Visit Windows  .......................................................................................................................... 18 
6.1.2  Study Days  ................................................................................................................................ 19 
7 RECRUITMENT METHODS  ....................................................................................................... 19 
7.1 PRELIMINARY REDCAP SCREENING  .............................................................................. 19 
7.2 CONFIDENTIAL PHONE SCREEN  ..................................................................................... 20 
7.3 EMAIL SCREENING PROCEDURES  ................................................................................... 21 
8 STUDY VISITS AND PROCEDURES  ......................................................................................... 21 
8.1 SCREENING VISIT  .................................................................................................................. 21 
8.1.1  Consent ...................................................................................................................................... 21 
8.1.2  Urine Collection  ....................................................................................................................... 22 
8.1.3  MILCOM  ................................................................................................................................... 22 
8.1.4  Vital Assessment  ...................................................................................................................... 23 
8.1.5  Screening Packet  ....................................................................................................................... 23 
8.1.6  Saliva Collection  ....................................................................................................................... 24 
8.1.7  End of Screening Visit  ............................................................................................................. 24 
8.1.8  Post -Processing  ......................................................................................................................... 24 
9 PREPARATION FOR INPATIENT PORTION ......................................................................... 25 
9.1.1  Product Purchasing  .................................................................................................................. 25 
9.1.2  5B Setup Paperwork  ................................................................................................................ 25 
9.2 ORIENTATION ........................................................................................................................ 27 
9.2.1  Product Assignment  ................................................................................................................ 27 
9.2.2  Distribution of Study Products  .............................................................................................. 27 
9.2.3  Product Use Diary  .................................................................................................................... 28 
9.2.4  Urine Collection  ....................................................................................................................... 28 
9.3 STUDY BLOCK #1  ................................................................................................................... 28 
Clinical Pharmacology of Electronic Cigarettes   IRB#  15-15992  
 4 9.3.1  Outpatient Days  ....................................................................................................................... 28 
9.3.2  Admission & Inpatient Days .................................................................................................. 29 
9.4 STUDY BLOCK #2  ................................................................................................................... 30 
9.4.1  Outpatient Days  ....................................................................................................................... 30 
9.4.2  Admission & Inpatient Days .................................................................................................. 31 
9.5 Summary of Standardized Puffing Protocols  ...................................................................... 31 
9.6 Product Weighing Procedures  ............................................................................................... 31 
9.7 PARTICIPANT COMPENSATION  ....................................................................................... 35 
10 ADVERSE EVENTS AND PROTOCOL DEVIATIONS  ........................................................... 35 
10.1 SAFETY MONITORING  ......................................................................................................... 35 
10.2 REPORTING ADVERSE EVENTS  ......................................................................................... 36 
10.3 PROTOCOL DEVIATIONS & VIOLATIONS  ...................................................................... 36 
11 DATA COLLECTION AND MANAGEMENT  ......................................................................... 37 
11.1 DATA COLLECTION FORMS  ............................................................................................... 37 
12 DUTIES AND RESPONSIBILITIES OF STAFF  ......................................................................... 38 
12.1 PRINCIPAL INVESTIGATOR ............................................................................................... 38 
12.2 CO-PRINCIPAL INVESTIGATORS  ...................................................................................... 38 
12.3 STUDY PHYSICIAN  ................................................................................................................ 38 
12.4 PROJECT MANAGER  ............................................................................................................. 38 
12.5 CLINICAL RESEARCH COORDINATOR ........................................................................... 38 
APPENDIX A: DATABASE GUIDE  ...................................................................................................... 39 
APPENDIX B: STUDY POST -MORTEM  .............................................................................................. 44 
 
 
 
 
 
 
Clinical Pharmacology of Electronic Cigarettes   IRB#  15-15992  
 5  
 
 
 
 
 
 
 
 
 
INVESTIGATORS,  PERSONNEL, CONTACT INFORMATION  
 
Benowitz, Neal L., MD       Principal Investigator  
        neal.benowitz@ucsf.edu  
        (415) 206-8324    
 
Dempsey, Delia A., MD      Co-Investigator  
Study Physician  
        delia.dempsey@ucsf.edu  
        (415) 641-1465   
 Goniewicz, Maciej, PhD, PharmD     Co-Investigator  
        maciej.goniewicz@roswellpark.org
 
        (716) 845-8541  
 
Jacob, Peyton, PhD       Co-Investigator  
        peyton.jacob@ucsf.edu  
        (415) 282-9495  
 St Helen, Gideon, PhD      Co-Investigator  
        gideon.sthelen@ucsf.edu
 
Clinical Pharmacology of Electronic Cigarettes   IRB#  15-15992  
 6         (415) 206-2687  
 
Nardone, Natalie, PhD       Project Manager  
        natalie.nardone@ucsf.edu  
        (415) 514-1450  
 Davis , Annalise                                                                                     Clinical Research 
Coordinator  
                                                                                                                  from May 2017-April 2018  
                                                                                                                  Annalise.davis@ucsf.edu  
 
Shahid , Marian                    Clinical Research Coordinato r   
                                                                                                                  from March 2015-April 
2017 
UCSF Tobacco Research Center     tobaccocoord@ucsf.edu   
        (415) 476-3555  
 
Tobin, Bernadette , RN      Nurse Manager  
        bernadette.tobin@ucsf.edu   
        (415) 206-3317  
 
SFGH CTSI – 5B       Front Desk  
        5BScheduling@sfghgcrc.ucsf.edu  
        (415) 206-8239  
 
BACKGROUND , GENERAL AIMS & STUDY DESIGN 
 
Electronic cigarettes (EC) are nicotine delivery devices that generate a nicotine -
containing aerosol which is inhaled by the user. EC are perceived by users to be useful 
in helping quitting smoking of conventional tobacco cigarettes (TC) as well as having a presumed lower risk of adverse health effects compared to TC, the potential for use in public places, reduced cost, and lack of the noxious clinging odors ass ociated with TC 
use. The use of EC has dramatically grown in recent years and is currently estimated to be a billion dollar industry, with over 400 existing brands of EC and the three major U.S. tobacco companies now marketing their own brands. The FDA has  announced the 
intention to regulate EC.  
  
Clinical Pharmacology of Electronic Cigarettes   IRB#  15-15992  
 7 Key questions relevant to FDA regulation include the addictiveness and safety of EC.  
Many believe that electronic cigarette (EC) function as nicotine delivery devices in the 
same way as tobacco cigarettes (TC), an d that EC will prove to be just as addictive as 
TC, but this may not be the case because of fundamental differences in the design and method of use of these products. For example, we hypothesize that systemic nicotine 
exposure will be lower with EC compare d to TC; that despite lower nicotine intake EC 
users will experience similar reward and no greater withdrawal symptoms or craving 
compared to TC; and that dual EC/ TC users will not titrate their daily intake of nicotine in the same way that TC smokers of high - vs low- yield nicotine TC do.  
  Our proposal specifically focuses on the areas that are thought to most closely relate to the addictive potential of EC, namely: (1) EC as nicotine delivery devices, covering issues of nicotine intake and pharmacokineti cs, temporal patterns of use and titration of 
nicotine; and (2) subjective effects of EC use, including relationship of use to reward, withdrawal and craving. We will also examine aspects of safety of EC use (by assessment of cardiovascular and hormonal ef fects of use and of biomarkers of 
exposure to potentially toxic constituents) and explore the identification and validation 
of biomarkers that may be useful in distinguishi ng EC from TC use. Study participant s 
will be dual users of TC and EC so that we may  compare both modalities of use in 
experienced users in a within -participant  design.  
  
The study will consist of two 1 -week blocks (EC -only or TC -only conditions) with 4 
days of outpatient ad libitum product use followed by 3 days in a clinical research wa rd 
to include a single -use pharmacokinetic study, monitoring of product use, subjective 
assessments, blood and urine collections to assess biomarkers, and a 24 -hour period of 
cardiovascular monitoring. Two additional days at the end of the 2nd block will a ssess 
similar measurements during a period of nicotine -product abstention.  
  
 
 
 
2 INTRODUCTION AND STUDY DESIGN 
2.1 RESEARCH QUESTION  
What are differences in the addictiveness and safety of electronic cigarette (EC) 
and tobacco (TC) use?  
Clinical Pharmacology of Electronic Cigarettes   IRB#  15-15992  
 8 2.2 SPECIFIC AIMS  
2.2.1 Specific Aim  #1 
To characterize nicotine delivery, systemic exposure and effects from 
Electronic C igarettes . 
In dual EC/TC users instructed to use only EC or TC for a week at a time, 
we will address the following questions:  
• What fraction of nicotine inhaled from EC  is retained in the body, and 
how is retention influenced by:  the type of device; the concentrations 
of nicotine, propylene glycol and glycerin in the e -liquid; the pH of 
the liquid; and the battery voltage? How does the time of peak 
nicotine concentration compare in EC vs TC use?  
• How does the amount of nicotine exhaled from EC use (important as 
a source of secondhand exposure to non -users) relate to the product 
characteristics?  
• What is the systemic exposure to nicotine from daily use of EC, and 
how is it influenced by the same product characteristics? How does 
exposure relate to the nicotine concentration of EC emissions as 
measured by smoking machine assays?  
• How does the daily intake of nicotine during ad libitum use compare 
for EC vs TC, and is there absolute or relative titration of nicotine 
intake when switching from one to the other? How much of the 
systemic nicotine dose from EC is absorbed via inhalation into the 
lungs and oropharynx vs swallowing into the gastrointestinal tract?  
• How do satisfacti on, reward, craving and withdrawal symptoms 
compare for EC vs TC use?  
• How does the pattern of puffing compare for EC vs TC use? Are there 
similar patterns of regular  vs clustered use within participant s? 
2.2.2  Specific Aim  #2 
To perform preliminary assessments of aspects of safety of E lectronic 
Cigarette  use. 
• What are the levels of exposure of tobacco smoke toxicants 
(particularly volatile organic compounds -  VOCs) for dual use 
(baseline) vs EC -alone vs TC -alone vs no -product use? What is the 
relations hip between propylene glycol (PG ), glycerin and nicotine 
concentrations in the e -liquid, the EC emissions, and the urine 
mercapturic acid metabolite products of propylene oxide and 
acrolein, respectively?  
Clinical Pharmacology of Electronic Cigarettes   IRB#  15-15992  
 9 • How do the cardiovascular effects (circadian heart rate, blood 
pressure and urinary catecholamine excretion) compare for use of EC -
alone vs TC -alone vs no -product?  
2.2.3  Specific Aim  #3 
To validate biomarkers useful in distinguishing E lectronic C igarette  use 
from T obacco C igarette  use. 
• What is the sensitivity and specificity of the ratio of nicotelline to 
nicotine metabolites (cotinine or total nicotine equivalents) in urine 
when used to distinguish EC vs TC use?  
3 STUDY DESIGN 
3.1 DESIGN SUMMARY 
This study is an observational, crossover study that will evaluate the 
addictiveness and safety of electronic cigarettes (EC). It will focus on the areas 
that are thought to most closely relate to the addictive potential of EC, namely: 
(1) EC as nicotine d elivery devices, covering issues of nicotine intake and 
pharmacokinetics, temporal patterns of use and titration of nicotine; and (2) 
subjective  effects of EC use, including relationship of use to reward, withdrawal 
and craving.  
3.2 MAJOR STATISTICAL VARIABLES   
Predictor Variable List: nicotine intake and pharmacokinetics (24 hour plasma 
nicotine area under the curve (AUC) during ad lib and total nicotine equivalents (TNEs) in 24 hour urine samples), temporal patterns of use (average and variability of inter -puff or inter -cigarette interval and the fraction of total daily 
units consumed in each of four 4 -hour intervals throughout the day), and 
titration of nicotine (ratios of 24 hour AUCs or 24 hour TNEs for EC/TC), levels of reward (CES), withdrawal (MNWS) and  craving (QSU) . 
Primary Outcome: concentrations of nicotine, cotinine, multiple nicotine metabolites in urine, the retention of nicotine, amount of nicotine exhaled, average daily nicotine intake, titration of nicotine intake and estimated swallowing vs inhalation of nico tine.  
Clinical Pharmacology of Electronic Cigarettes   IRB#  15-15992  
 10 Refer to Page 3 of the Data Safety and Monitoring Plan for secondary and tertiary 
outcomes.  
3.3 PRIMARY RESEARCH SAMPLES  
Plasma: nicotine, cotinine, 3- Hydroxicotinine (3HC), IL -6, C-reactive protein, s -
ICAM, angiopoietin -2 and vascular endothelial g rowth factor (VEGF).  
Urine: nicotine, nicotine metabolites (nicotine equivalents), NNAL, catecholamines, mercapturic acid biomarkers of acrolein and propylene oxide, 
and other volatile organic compounds (VOCs), minor alkaloids (including 
anabasine, anatabine , and nicotelline), 8 -iso-PHF alpha, 11- dehydro -TxB2 .  
A detailed Schedule of Assessments outline number of samples and assays is located in the Crossover Study folder on the t- drive under Databases.  
3.4 STUDY TIMELINE  
• Application  submitted to the Institution al Review Board ( IRB): 3/19/2015 
• Approval date:  3/23/2015 
• Expiration date:  3/22/2018  
• Dates of enrollment:  12/7/2015- 2/2/2018 
3.5 ELIGIBILITY  
Potential p articipants will express interest in participation by calling the UCSF 
Tobacco Research Center Recruitment Line, filling out the secure REDCap survey hyperlink from the Craigslist ad, or by emailing the UCSF Tobacco Research Center email address. Parti cipants will be contacted to take  part  in a confidential 
phone screen or email s creening to determine if they a re eligible to come in for an 
in-person screening visit. At the in -person screening visit, participants will fill 
out case report forms  (TC & EC  use, medical history , etc. ), the  Clinical Research 
Coordinator  (CRC)  will take  physiological measure ments (blood pressure, 
height, weight, expired CO, etc.), and  the participant s will provide  sample 
collections (urine and saliva). The participant’ s study chart will be reviewed by 
the S tudy P hysician in order to determine study eligibility.  
All individual s interested in participating and who meet the inclusion/exclusion 
criteria will be invited to be part of the study. Inclusion criteria are described below.  
Clinical Pharmacology of Electronic Cigarettes   IRB#  15-15992  
 11 3.5.1   Inclusion Criteria  
• Healthy on the basis of medical history and limited physical examination .  
o Heart rate < 105 BPM *  
o Systolic Blood Pressure < 160 and > 90*  
o Diastolic Blood Pressure < 100 and > 50*   
*considered out of range if both machine and manual readings are above/below these 
thresholds  
o Body Mass Index ≤ 38.0 
• Current regular “dual” user of bot h EC and TC  
o Using same EC device at least 15 days out of the past 30 days  
o Nicotine strength of e -liquid ≥ 6 mg/mL , if using a  2nd or 3rd 
generation  device, or willing to use a 6mg/mL strength e -liquid for 
the duration of the study 
o Conventional TC ( ≥ 5 CPD for past 30 days)  
o Carbon monoxide ≥ 5 ppm  or per discretion of  Principal Investigator  
o Saliva cotinine ≥ 50 ng/mL  or urine cotinine via NicAlert  
• EC device is one of the most popular 1st, 2nd, or 3rd generation brands  (with 
the exception of rebuildable atomizers)  as determined at time of study 
commencement  
• Age: ≥  21 years  old  
3.5.2   Exclusion Criteria  
• Medical  
o The following unstable medica l conditions :  
 Heart disease  
 Uncontrolled hypertension  
 Thyroid disease  
 Diabetes  
 Hepatitis B or C or Liver disease  
 Glaucoma  
 Prostatic hypertrophy  
• Psychiatric   
o Current or past schizophrenia, and/ or current or past bipolar disorder  
o Adult onset ADHD (if being treated)  
o Participants with current or past depression and/or anxiety dis orders 
will be reviewed by the S tudy P hysician and considered for inclusion  
Clinical Pharmacology of Electronic Cigarettes   IRB#  15-15992  
 12 o Psychiatric hospitalizations are not exclusionary, but study 
participation will be determined as per S tudy P hysician’s approval 
• Drug/Alcohol Dependence  
o Alcohol or illicit drug dependence within the past 12 months with the 
exception of those who have recently completed an alcohol/drug 
treatment program  
o Positive toxicology test at the screening visit (THC okay)  
o Methadone replace therapy  
• Psychiatric M edications  
o Current regular use of any psyc hiatric medications with the exception 
of SSRIs and SNRIs and current evaluation by th e Study P hysician  that 
the participant is otherwise healthy, stable, and able to participate.  
•  Medications  
o Use of medications that are inducers of nicotine metabolizing enzyme  
CYP2A6  (Example:  rifampicin, dexamethasone, phenobarbital, and 
other anticonvulsant drugs ) 
o Use of medications for cardiovascular cond itions including 
hypertension (E xample: beta and alpha- blockers)  
• Other/Misc . Health Conditions  
o Oral thrush  
o Fainting  
o Untreated thyroid disease  
o Other “life  threatening illnesses” as per S tudy P hysician ’s discretion  
• Pregnancy  
o Pregnancy (self -reported and urine pregnancy test)  
o Breastfeeding (determined by self -report)  
• Use of Other Tobacco Products (OTP)  
o Any of the following products in combination more than 15 times in 
the past month  
 smokeless tobacco  
 pipes  
 cigars , cigarillos  
 blunts, spliffs   
• Concurrent use of nicotine -containing medications  (Example: nicotine 
patch, lozenge, gum)  
• Concurrent participation in another clinical trial . 
Clinical Pharmacology of Electronic Cigarettes   IRB#  15-15992  
 13 • Inability to communicate in English . 
• Planning to quit smoking within the next 60 days   
 
3.5.3    Eligibility Determination  
After completion of in -person screening proce dures, the CRC will complete an  
Eligibility Checklist  which lists all inclusion/exclusion criteria and the 
participant’s status based on responses in the case report forms . The Project 
Manager and CRC will review the Eligibility Checklist after the saliva cotinine 
results are available.  
The Project Manager and CRC will refer to the Study Physician or Principle 
Investigator if  the participant : 
• Currently takes  any medications on schedule or as needed  
• Has current or  past depression and/or anxiety disorders  
• Has any p sychiatric hospitalizations  in medical history  
The Study Physician will review the inform ation and sign off on the Eligibility 
Checklist or indicate that the participant is ineligible . If none of the above 
conditions are present , the CRC and Project Manager will sign off on Eligibil ity 
Checklist  without Study Physician review .   
The participant will be notified of eligibility via phone or email after this 
review.  
3.5.4 Reassessment of Eligibility  
Eligibility may  need to be reassessed if the following conditions occur: the 
orientation visit is out of window  (e.g. 90 days past from screening visit) , and/or 
30 days have passed since the  time of the screening visit.  
3.54a  Outside Orientation Visit Window  
If the pa rticipant is outside of their orientation visit window of 90 days, the 
screening visit will be repeated. The original screening visit data will remain in the study chart, however it will not be used for analysis. T he participant  
will repeat all visit proce dures, forms, and  provide a saliva sample to be re -
sent for analysis .  
Clinical Pharmacology of Electronic Cigarettes   IRB#  15-15992  
 14 3.54b  30 Days Past  Screening Visit  
If 30 days have  passed since the screening visit, i n order to ensure that no 
significant changes have occurred in a participant’s current medical status 
and smoking /vaping  habits, the CRC will review some eligibility items . This 
will occur if the  participant is more than 30 days, but les s than 90 days 
outside of their screening visit  window . The CRC will ask the following over 
the phone :  
• if there a re any new medications  
• if they have seen a physicia n for any medical/psychological  
reason  
• if they are still using their e -cigarettes and tobacco cigarettes as 
indicated at the in -person screening visit  
If any significant changes have occurred, the CRC and Project Manager will 
meet to discuss and complete another Eligibility C hecklist based on current 
participant responses.  
4 IDs & Assignment  
4.1.1 Study IDs  
At the start of the  phone screen, participants will automatically be  assigned  a 
REDCap  ID which will start at the number “1” and be in sequence of the order of 
participants screened.  The email screen database will also be numbered 
sequentially by participant, starting at 1000. These two REDCap databases will later be merged to become one  database contain ing all entries for those screened 
by phone and by email  for this study. Participants  will be assigned a REDCap ID 
regardless of their eligibility status.   
Participants who  are eligible for an in -person screening visit will be assigned a 
unique S tudy ID upon consent to participate in the study.  This S tudy ID will 
begin with the “6885” to refer  to the CTSI -5B study number, which is how the  
study is referred to at the research ward. These numbers  will be followed 
sequentially starting fr om 001. For example, the first participant enrolled will 
have a Study ID of 6885- 001.  
Clinical Pharmacology of Electronic Cigarettes   IRB#  15-15992  
 15 The Screening Visit Log will keep track the REDCap IDs, and S tudy  IDs (if 
consented). This log will be maintained as a hard and electronic copy.   
4.1.2 Assignment Procedure  
The participant  will be assigned  to one  of two groups:  
1) Electronic Cigarette (EC) only for Study Block #1 and Tobacco Cigarette 
(TC) only for Study Block #2.  
OR 
2) Tobacco Cigarette (TC) only for Study Block #1 and Electronic Cigarette (EC) only for Study Block #2.  
The participant will not be considered for assignment unt il it has been verified 
that he/she  is eligible and the Eligibility Checklist has been signed. The 
participant will be tentatively assigned to one of the two groups when he/she  is 
scheduled for an orientation visit.  
The CRC will purchase both tobacco and e -cigarette products in case the 
assignment changes. The final product assignment will take place at the 
orientation visit. T he CRC will refer to the “6885 Eligible Participants Log ,” input 
the participant’s initials, product assignment, and date he/she  is assigned to that 
condition.  Assignment does not necessarily reflect the sequence of the 
participant’s consent  in the study, but rather when he/she is  booked for the start 
of orientation. That time course will vary based upon participant, CRC and CTSI 
availability.  
If a participant drops out or is lost to follow -up (LTFU ) during the study, he/she  
will not be replaced. The assignment schedule will continue as assigned, and the PI can decide to enroll additional participants to compensate for non -completers.  
Study group assignment will be based on the following Assignment  Schedule : 
(NOTE: Participant  ID in the tabl e below may or may not correspond to 
Participant  Study ID)  
Clinical Pharmacology of Electronic Cigarettes   IRB#  15-15992  
 16  
5 PARTICIPANT WITHDRAWAL  
5.1.1 Dropout Definition  
If a participant declares he/she is  no longer interested in completing the study, 
he/she  will be considered a “dropout.” Once given “dropout” status, the 
participant can no longer contribute to the study.  
5.1.2 Dropout Compensation 
If participant decides to stop participating in the study prior to starting the 
inpa tient portion of the study, he/she  will only receive compensation for the 
Screen ing Visit ($30) and no compensation will be given for the inpatient portion.  
If a participant decides to drop out during the inpatient study, compensation will 
be as follows:  
• Inpatient  admission Study Block #1  

Clinical Pharmacology of Electronic Cigarettes   IRB#  15-15992  
 17 o Day 1 -  $200 
o Day 2 -  $400 
o Day 3 -  $600 
If the participant does not complete the early morning procedures on the 
morning of Day 4 before discharge, he/she will still be compensated $600 for 
comp letion of the full study block   
• Inpatient  admission Study Block #2:  
(amounts would also includ e + $600 for completion of Study Block #1)  
o Day 1 -  $180  
o Day 2 -  $360  
o Day 3 -  $540  
o Day 4 -  $720 
o Day 5 – N/A, participant  would get full $ 900 +$500 bonus  
“Day” indicates a full 24 hours of procedures. If the p articipant  leaves in less 
than 24 hours of that day, the CRC and P roject M anager  will discuss providing 
compensation for a partial amount.  
5.1.3 Lost to Follow -Up 
If a participant is unable to be contacted and does not respond to calls from the 
Clinical Research Coordinator, he/she will be considered “lost to follow -up” 
(LTFU). If a participant is considered LTFU, every effort will be made to contact him/her.  
5.13a  Contact Attempts  
After three unsuccessful phone and email contact attempts, a letter of intent to c ontact will be mailed to the participant’s home address. This 
letter will inform the participant that they will be formally withdrawn from the study  by the date that is 90 days past the last point of contact.  It 
will also include details on the remaining study compensation available  if 
procedures were continued . If the participant fails to contact the CRC after 
this outreach,  and 90 days have passe d since last communication, he/she  
will be  considered “lost to follow -up”. No further outreach will be 
conducted.  Once given “LTFU” status, the participant can no longer 
contribute to the study.  
Clinical Pharmacology of Electronic Cigarettes   IRB#  15-15992  
 18 5.13b  Returning to Visit Procedures  
If a formerly lost participant returns, before starting the inpatient portion 
of the study, the reassessment of eligibility steps outlined in Section 3.5.4 
of this manual will be followed. If the participant is LTFU during some 
point in his/her inpatient portion, there will not be the option to repeat this.  
6 VISIT SCHEDULE   
The Study Visit chart below describes the schedule of vi sits and procedures .  
 
6.1.1 Visit Windows  
Table 1 describes the schedule of visits in relation to the  start point of the 
Phone/Email Screen. Ideally, participant assessments will fall within the 
designated windows.  
   
  Table 1  
Assessment Point  Maximum Time 
allowed from  
Phone /Email  Screen  Maximum Time 
allowed from 
Screening Visit  

Clinical Pharmacology of Electronic Cigarettes   IRB#  15-15992  
 19 Phone/Email Screen    
Screening Visit  30 days   
Orientation  120 days  90 days  
Every effort should be made to enroll and run eligible participants. Thus, if 
participants are outside of their screening visit or orientation visit window s, 
reassessment of eligibility will occur  as described in Section 3.5.4.  
6.1.2 Study Days  
Due to CTSI closure on weekends, participants must come in for their  
Orientation Visit  on a  Thursday morning. Orientation Visits conducted on 
Thursday mornings allow for the first and second inpatient admissions to take place on Monday mornings  without the issue of we ekend closures , and allow  for 
study completion on Fridays .  
7 RECRUITMENT METHODS 
Our methods of recruitment will be as follows:  
• Postings to craigslist (paid and free sections)   
• Flyers posted in mostly institutional settings (colleges, career centers, 
churches)  and left at vape and smoke shops  
• Newspaper ads (typically Bay Guardian, SF Weekly, East Bay Express)  
• Blogs, google+ and social networking sites  
• Contact of prior callers or study participant s who have given permission for 
re-contact as documented  either in the consent form for the prior study or in 
our phone screening database.  
Individuals  who respond to recruitment postings/flyers will be screened by phone 
or email to determine potential eligibility. B ased on this initial assessment they 
may be a sked to come to the UCSF  Tobacco Research Center for an in -person 
screening  visit. Additionally, participant s from previous studies at the UCSF 
Tobacco Research Center, who appear to be eligible for the study will be re -
contacted and asked if they are interested i n partic ipating . 
7.1 PRELIMINARY REDCAP SCREENING  
Individuals who see the ad  through Craigslist will be prompted to click on a 
hyperlink which will lead them to a preliminary screen on REDCap , or email the 
UCSF Tobacco Coordinator address  for more information .  
Clinical Pharmacology of Electronic Cigarettes   IRB#  15-15992  
 20 The preliminary REDCap screen  (“UCSF Tobacco Research Email Screen ”) is a 
short survey in which the participants provide the following information:  
• Contact information  
• E-Cigarette/Tobacco Cigarette product use  
• Prescription Medicatio n Use  
• Exclusionary medical conditions  
This REDCap survey is programmed to generate a report of eligible participants. 
For example, a parameter is  set for cigarettes per day to only includ e participants 
who smoke ≥5 cpd  in the report . The information for eligible participants will be 
exported weekly from REDCap into an E xcel sheet.  The CRC will  use this 
information to call  only  valid prospects , and schedule these participants to come 
in for an in -person screening visit .  
7.2 CONFIDENTIAL PHONE SCREEN  
At the beginning of this study, a Conf idential Phone Screen was used  before 
migrating exclusively to the REDCap Screening. The CRC will c all eligible 
individuals , as described above, to conduct a thorough Confidential Phone 
Screen. Additionally, individuals who call the UCSF Tobacco Research Center 
Recruitment Line  directly  will undergo  the phone screen . Data generate d from 
this phone screen will be entered into REDCap. The CRC will ex plain that 
questions will be asked regarding the individual’s tobacco product use and health history, and that the expected length of the screen  is approximately  10 
minutes.   
Procedures for the Confidential P hone S creen include the following:  
• The CRC will  record the participa nt’s personal information in a secure  
Access Database. This includes their  name, phone number, email address, 
date of birth, and address.  
• After completing the Access Database fields, the CRC will open REDCap and start a new entry. The REDCap ID number that populates will be copied into the Access Database to connect the personal information to the screening data. No identifiers are recorded in REDCap .   
• The CRC will administer a series of eligibility questions, collected in the Phone Screen REDCap form (“E -Cigarette R01 & Flavors Study Screen ”).   
• The CRC will determine if the participant is eligible to attend an in -person 
screening visit based on the inclusion/exclusion criteria.  
Clinical Pharmacology of Electronic Cigarettes   IRB#  15-15992  
 21 If the participant is ineligible during the phone scree n, the CRC may choose to 
end the phone screen when appropriate. In the even t of an eligible participant, an 
in-person screening will be scheduled immediately.  
7.3 EMAIL SCREENING PROCEDURES  
Individuals who email the UCSF Tobacco Coordinator email address for more 
information about the study  will receive an email asking them to complete a 
survey via REDCap. This survey will serve to determine their eligibility to attend 
an in- person screening visit.  
Procedures for the email screen include the following:  
• The CRC will respond and ask the participants to complete the RED Cap 
Email Screening S urvey  (“Crossover Study Email Screen”) . The REDCap 
Email Screening Survey has all of the same questions as the Confidential 
Phone Screen, but is in a survey format that t he participant s will fill out 
themselves.  Additionally, it contains a field for email addresses, so the CRC 
can connect participants via their email addresses to their responses.   
• A report in the REDCap Database will generat e a list  of eligible 
participants .  
• If eligible, t he CRC will  call the participant to schedule them to com e in for 
an in- person screening.  
8 STUDY VISITS AND PROCEDURES  
8.1 SCREENING VISIT  
Participant s will undergo a 1 -2 hour in -person screening v isit to determine study  
eligibility. During this visit, participants will complete a basic physical assessment: height, weight, heart rate, blood pressure, expired carbon monoxide, urine toxicology test, and pregnancy test (if applicable), saliva collection, a 
MILCOM, and a Screening P acket containing questions regarding medical 
history and product use. Photographs of the participant s’ e-cigarette and e -liquid 
will be taken.  
The schedule of procedures for the screening visit will occur in the order as 
follows:  
8.1.1 Consent  
Upon in itiation of  the screening  visit, the CRC will greet the participant and  ask 
to see a valid form of identification to verify their age.  Next, the CRC will ask 
Clinical Pharmacology of Electronic Cigarettes   IRB#  15-15992  
 22 him/her  to read the first line of the consent form aloud to confirm literacy . The 
CRC will instruct the participant to read each page of the consent document and 
initial at the bottom of each page indicating content understanding. The participant  will be asked to refrain from signing the consent form until the CRC 
returns to discu ss the consent form and answer any questions the participant 
may have regarding the study. The CRC will leave the room for  approximately 
10 minutes to allow  the participant an adequate amount of time  to read the 
consent form. The CRC will return, answer an y questions, and present a brief 
PowerPoint presentation highlighting important aspects of the consent document. Consent wi ll be obtained via participant and CRC  signature s at the 
conclusion of the presentation. Two copie s of the consent document will  be 
signed  and dated by both the participant and the CRC. The CRC should retain 
the initialed copy and the second copy, and the third copy will  be given to the 
participant for their  records. Additionally, the participant will be asked to review 
and sign two HIP AA forms, and a third copy will be given to the participant for 
their records.  The participant will also be asked to read a copy of the Bill of Rights to ensure  that the participant is  aware of his/her  rights in participating in 
a research study.  
8.1.2 Urine Collection  
After consent , the participant  will be asked to provide a urine collection to test 
for drug use and pregnancy  testing (if female).  
If the participant ha s a positive toxicology screen (marijuana is okay), he/she  will 
be dismissed and given the option to rescreen within 30 days.  
The steps for the urine collection toxicology and pregnancy screenings are found in the “Urine Toxicology Screen SOP” and “Pregnancy Screen SOP.”  
8.1.3 MILCOM  
After confirming a negative toxicology screen and negative pregnancy screen, the participant  will be asked to complete the MILCOM , a comprehensive Health 
History Questionnaire.  
• Follow -up is required if any symptoms are endorsed on the MILCOM in 
the following Sections :  
o Additional Illness or Problems  
o Head and Neck  
o Respiratory  
o Cardiovascular  
o Musculoskeletal  
Clinical Pharmacology of Electronic Cigarettes   IRB#  15-15992  
 23 o Skin  
o Neurological  
o Mood  
The CRC will follow up with the participant asking : 
o How often and when was the last time you experienced th ese 
symptom s?  
o Do you ever take medication for this? If  so, how often?  
Notes on the MILCOM f ollow -up will be recorded in empty space on the form .  
8.1.4 Vital Assessment  
The fo llowing physiological measures  will  be assessed : 
• Height and Weight  
• Blood pressure and heart rate  
• Expired carbon monoxide (CO)  
Steps for these assessments are found in the “Measuring Basic Vitals SOP” and 
“Measuring Expired CO Levels SOP.”  
If the participant ’s blood pressure is out of range, it will be re -tested at the end of 
the visit manually, following the saliva collection. If it is sti ll out of range, they 
will be considered ineligible. If the participant ’s expired CO levels are not ≥ 5 
ppm , CRC may proceed with screening visit and the PI will use their discretion  
to determine eligibility.   
8.1.5 Screening Packet  
The screening packet will then be administered. It is broken into four main parts:  
• Section 1: Personal Data Form   
o This section contains the participant’ s contact information as well as 
an Emergency Contact.  
• Section 2: Demographics   
o This section contains information regarding the participant’s gender, 
age, ethnicity, race, and education. 
• Section 3: Tobacco Product Use   
o This section contains information regarding participant’s use of nicotine replacement therapy, tobacco and e -cigarette product use, 
and drug/ alcohol use.  
• Sectio n 4: Medical History   
Clinical Pharmacology of Electronic Cigarettes   IRB#  15-15992  
 24 o This section contains information regarding the participant’s medical 
history, including exclusionary medical and psychiatric conditions.  
o If any symptoms are endorsed on the Medical History in Section 4  
the CRC will follow up with th e participant asking:  
 How often and when was the last time you experienced th ese 
symptom s?  
 Do you ever take medication for this? If so, how often?  
Notes on the Medical History f ollow -up will be recorded at the bottom of the  last 
page of the form .   
The steps for administering and reviewing questionnaires are found in the “Administering Forms and Questionnaires SOP.”  
8.1.6 Saliva Collection  
After the participant comp letes the Screening Packet, he/she will be asked to 
provide a saliva collection. The steps for t he saliva collection are  found in the 
“Saliva Collection SOP.” 
8.1.7 End of Screening Visit  
At the end of the screening visit, the participant  will be asked to fill out a 
“Certificate of Participation” in order to receive compensation for the screening 
visit. The participant  will be  dismissed and the CRC will inform him/her  that 
he/she  will be contacted in 1 -2 weeks with eligibility res ults from the  screening 
visit.  
8.1.8 Post -Processing  
The participant’s urine will be discarded and the  CRC will store the participant’s 
saliva in the freezer at the UCSF Tobacco Research Center lab. The saliva samples will be labeled with the Study ID and tr ansferred to the Benowitz Lab  at the end 
of the day on Friday afternoons . The CRC will complete a Sc reening Log on the 
Shared Lab Drive filling in information on the samples dropped off. Cotinine results will be expected the following Tuesday .  
The MILCOM will remain a source document and  will  not be entered into an 
electronic database. The CRC will comp lete the Screening  Visit Log  (#6885 
Participant Log & Tallies)  and enter data from the Screening Packet into the 
“Crossover Screening Packet” REDCap database. Data entry should occur within 48 hours of the screening visit.  
Clinical Pharmacology of Electronic Cigarettes   IRB#  15-15992  
 25 The CRC will submit the particip ant’s check request after confirming the 
participant’s smoking/vaping status (COT ≥ 50 ng/m L).  If the  participant ’s 
cotinine  is <50 ng/ml, they will not be compensated for their screening visit.  
9 PREPARATION FOR INPATIENT PORTION  
9.1.1 Product Purchasing  
The CRC will purchase the participant’s EC or TC products from local vape  or 
smoke  shops using a petty cash fund. The CRC will purchase enough products to 
be used for the participant’s 4 outpatient days, inpatient study days, and for lab 
analysis. In order to det ermine total TC products, the CRC will refer to the 
Screening Packet, Section 3: Tobacco Smoking History, question #8 for cigarettes per day. In order to determine total EC products, the CRC will refer to Screening Packet, Section 3: E -Cigarette History, q uestions #4 and #6 in order to get a 
proper approximation of how much e -liquid the participant uses per day. Refer 
to Section 9.2.2. for description of the calculations.  
9.1.2 5B Setup  Paperwork  
After study dates have been confirmed with the participant and the  research 
ward, an admission request will be submitted via secure email to the research 
ward. The CRC will then prepare CTSI -5B Set -up paperwork for the admissions.  
The set -up paperwork consists of the following:  
Coversheet  
• The coversheet contains general  information regarding the study 
and supplies needed.  
• CRC will place a label with the participant’s name and study ID, 
and edit the admission and set -up drop- off dates.  
Consent Form  and HIPAA  
• An original signed copy of the consent form  and HIPAA  from the 
Screening Visit will be included in the set -up. 
Nurses Flow Sheet  
• The Nurses Flow Sheet contains study procedures and time points for each day of the inpatient admission.  
• CRC will update this form with participant’s TC and EC product brands.  
Clinical Pharmacology of Electronic Cigarettes   IRB#  15-15992  
 26 MD Orders  
• The M D Orders are pre -signed by the S tudy Physician that will 
conduct the physical during the admissions.  
• CRC will write in the admission date and pencil in the participant’s 
name on the top right corner.  
Admit PE  
• The Admit PE will be filled out by the  Study  Physician as they 
perform the history and physical.  
• CRC will pencil in participant’s name in the top right corner.  
Adverse Event Form  
• The Adverse Event form is included in the set -up should any 
adverse events occur during the course of the study.  
• CRC will  change the study ID . 
                      Other Study Forms  
• Caffeine Log  is included to track participants’ inpatient caffeine 
intake  
• Study Questionnaires  included are the following:  Questionnaire of 
Smoking Urges (QSU), modified for E -Cigarettes Cigaret te 
Evaluation Scale (mCES), Positive and Negative Affect Scale (PANAS), and Minnesota Behavioral Scale (MNWS)  
• The Outpatient W ithdrawal  Form is used to describe symptoms 
that participants felt over the outpatient study period (Thursday-Sunday).  The Withdrawal Form asks participants to rate their symptoms on a scale of 1 -5.  For participants who rated any given 
withdrawal symptom as being a 3 or 4, the CRC followed up with the participant to ask which outpatient days they had those symptoms, and if any day was more intense than any other.  These notes were recorded next to the c orresponding item on the form.  
• The 48- Hour P roduct U se Form w as intended to be used to track 
outpatient product use in cases where participants did not fill out their product diaries over the outpatient period.  This form was kept on hand, but never used for any of the participants.  
• The End of Study Questionnair e wa s given to participants on the 
final day of the study in the second block, and asked about their compliance with study procedures during the study.  
Clinical Pharmacology of Electronic Cigarettes   IRB#  15-15992  
 27 9.2 ORIENTATION  
Participants  will attend  an Orientation Visit on a Thursday,  to begin their 
Outpatient Days in Study Block #1. This visit will last approximately 1 hour . 
During the Orientation V isit, study procedures will be described in detail again. 
The followi ng will take place : 
9.2.1 Product Assignment  
The CRC will input the participant’s initials, product assignment, and date 
he/she is  assigned to that condition into the “6885 Eligible Participants Log ”.  
Product assignment  procedure s are described in Section 4.1.2.  
9.2.2 Distribution of Study Products  
Participants will be given EC or TC products (based on assign ment schedule ) to 
use for the 4 outpatient days prior to their admission to the CTSI -5B research 
ward.  Before distribution, the CRC will weigh all of the products.   
For the 1st generation  EC users, the EC  device as well as the cartridges (if 
applicable)  will be provided in the participant’s preferred flavor.   For 2nd 
generation, we will only provide  the e -liquid vials.  In the case of multiple e -
liquid vials or cartridges, each vial/cartridge w ill be numbered with a label or via  
a sharpie pen before weig hing .   
 The amount of devices  or cartridges  to provide  will be  estimated using the 
participant’s self - reported daily product usage on their screening packet.  Light 
to medium users  will be  given 1 vial or 3 cartridges to use over the outpatient 
period, and 1 vial or 3 cartridges will be  purchased  for their use during the 
inpatient period.  Heavier users will be  given 2 vials or 5 cartridges to use over 
the outpatient period, and 2 vials or 5 cartridges will be  purchased for their  use 
during the inpatient period .  Before distributing any of the devices/cartridges or 
e-liquid vials, they will be labeled  with a sharpie and this weight will be 
recorded on the center of the Product under “Ad Lib Use”.  The weight of that 
distributed e -liquid or cartridge  after the participant’s use upon collection the 
following day can be found below  the Ad Lib Use section under “Returned 
Products”.  
For the TC products , the number of cigarette packs provided will  be determined 
by  the participant’s self -report ed cigarettes per day on their Screening P acke t, 
plus additional cigarettes to account for their exclusive use of one product.  The 
amount to purchase for both outpatient and inpatient will be calculated as : 
(cigarettes per day * 7) + 1 pack, rounded to near est pack.  The participants will be 
asked to collect their cigarette butts during their outpatient and inpatie nt study 
Clinical Pharmacology of Electronic Cigarettes   IRB#  15-15992  
 28 days.  These butts will be  collected and weighed.  The weights for the cigarette 
butts c an be found on the TC Product Weights form.    
Participants will sign a product accountability form and be instructed to return 
all empty and unused products at the end of their outpatient period.    
9.2.3 Product Use Diary  
Participants will be asked to keep trac k of their product use during their 
outpatient days. Instructions for using the TimeJot  app or paper diary will be 
reviewed at the Orientation Visit.  
As the TimeJot app is not compatible with an Android phone, participants who 
own an Android will use a paper diary.  On the paper diary, they will record their smoking start and end time, and how many puffs they take.  At the end of each outpatient day, the participant will take a picture of the paper diary and email it to the CRC . 
For the TimeJot app, p articipants will be instructed to select a pre -programmed 
button on the TimeJot app that records the participants’ smoking/vaping sessions. Participants will select the “Start” button when they begin a smoking/vaping session and a “Stop” button when they e nd. The information 
recorded in the TimeJot app is the date and duration of the sessions in seconds. Participants will email the final report to the secure UCSF Tobacco Coordinator 
email address  at the end of the day, after their last vaping/smoking sessions .  
9.2.4 Urine Collection  
Participants will provide a urine collection to be tested for nicotine by- products.  
This urine collection  will amount to 40mL. The CRC will adjust the urine pH, 
label, and store the urine in the UCSF Tobacco Research Center lab. The s teps for 
adjusting the urine pH are found in the “Adjusting Urine pH SOP.”  
9.3 STUDY BLOCK #1  
9.3.1 Outpatient Days  
After the Orientation Visit, par ticipants will begin their 4  outpatient days and use 
the product assigned at randomization. They will track their product use with the TimeJot app or paper diary, recording every time they start/stop a TC or EC 
session . After they have completed their use for the day,  they will email the 
summary report to the CRC. If participant s have not emailed  their summar ies by 
the following morning, the CRC will send the m a reminder email.  
Clinical Pharmacology of Electronic Cigarettes   IRB#  15-15992  
 29 9.3.2 Admission & Inpatient Days  
After the 4 outpatient days, participants will check into the San Francisco 
General Hospital Clinical Research Center on the morning of Study Block #1, Day 
#5 at approximately 7am.  As required for all hospital admissions, participants 
will have a medical history and phy sical examination conducted by the S tudy 
Physician . 
On Day #5 , the following will occur:  
• A plastic catheter (thin flexible tube) will be inserted into a vein on the participan t’s forearms (this will be used to withdraw multiple blood samples 
and will be kept in place for about 10 hours). The participant will be given a light breakfast and, if he/she  normally drink s caffeinated beverages, he/she  
will be allowed a cup of his/her  usual beverage (coffee or tea).  
• Between 8:50- 9:00am  (depending on the assigned study product) , the 
participant  will be asked to smoke a commercial cigarette or e -cigarette 
device and to take puffs only at times signaled by the voice recorder  or 
research team .  
o If this is an e -cigarette device the puffs will be directed as follows: 
taking one puff ev ery 30 seconds for a total of  15 puffs on 1
st 
generation devices and  10 puffs  on 2nd/3rd generation devices .  
o If this is a tobacco cigarette, puffs will be directed as follows: taking one puff every 30 seconds until cigarette is consumed .  
• After each puff, we will capture the smoke the participant  breathe s out by 
asking him/her  to exhale into a sterile polypropylene mouthpiece which is 
connected to 3 gas traps. The gas traps are connected in series (i.e. in a line) and contain diluted hydrochloric acid or a solution containing citric acid, sodium phosphate, and ascorbic acid. A vacuum pump connected to the traps will suck the  exhaled smoke into the traps. There will be NO contact between 
the participant’s mouth or  body with the diluted acidic solution in the gas 
traps. This step will allow us to compute the dose of nicotine taken  in from 
the cigarette during the standardized session.  
• The participant  will not be allowed to smoke again until 4 hours later, at 
which time he/she  will be given his/her  usual TC or EC  and allowed to smoke 
it as he/she  wish es.  
• Blood samples, about one t easpoon each, will be wit hdrawn just before 
smoking, and  after the standardized session . Then during the 4 -hour 
abstinence period, blood draws will take place at 2, 5, 15, 30, 45, 60, 90, 120, 
180, and 240 minutes.  
Clinical Pharmacology of Electronic Cigarettes   IRB#  15-15992  
 30 • The participant  will  also  be asked to fill out several Questionnaires about 
his/her  smoking experience before and after smoking the TC/EC  and during 
the 4 hours when he/she is  not smoking.  
• The participant  will not be allowed to doze or sleep during the day. The CRC 
or nurse may w ake the participant if they appear to be sleeping.  
 
On Day #6 , the following will occur:  
• The participant will be allowed to smoke his/her  cigarettes or electronic 
cigarette device as desired from 8am to 12am midnight.  
• The time of each cigarette or EC puff will be recorded using the TimeJot 
smartphone app  or paper diary  and all cigarette butts and EC devices will be 
collected at the end of the day to determine product usage.  
• The participant  will wear a 24- hour ambulatory  blood pressure and heart rate 
recorder for cardiovascular monitoring . 
• The participant  will also be asked to fill out several Questionnaires.  
• There will also be 24 -hour urine collections.  
 
On Day #7 , the following will occur:  
• On the morning of Day #3, an intravenous catheter (like on Day #1) will be placed for blood collections every four hours from 8am to midnight, and at approximately 8am the next day.  
• The participant  will  also  be asked to fill out several Questionnaires.  
• There will also be 24 -hour urine collections.  
• The participant will be discharged the following morning (Study Block #2, 
Day #1) after his/her  last blood draw and urine collection.  
9.4 STUDY BLOCK #2  
9.4.1 Outpatient Days  
After being discharged from the research ward, participants will be able to use 
their electronic cigarette device or tobacco cigarette product as they wish for  
another  4 outpatient days. Just as in the outpatient days for Study Block #1, they 
will use track their product use with a smartphone dia ry app or paper diary.   
During this outpatient period, the CRC will closely monitor participants ’ entries 
in the TimeJot app  or paper diary , as described in Section 9.2.3.  
Clinical Pharmacology of Electronic Cigarettes   IRB#  15-15992  
 31 9.4.2 Admission & In patient Days  
The second inpatient admission will follow the same structure as the first 
inpatient admission mentioned above, but instead the participant will be admitted for a period of 5 days using the alternate product.  
The first 3 days of the admission will follow the same procedures as the first admission, with an a dditional two day abstinence period in which the 
participant will be asked not to use any products. During the abstinence period, there will be 24 -hour urine collections , 24-hour cardiovascular monitoring , and  
Questionnaires.  
On Day #8, the following will  occur:  
• The participant  will abstain from all product use.  
• The participant  will fill out several Questionnaires.  
• 8-hour urine collection  from 8am -4pm followed by a 24- hour urine collection  
begin ning  at 4pm . 
• 24-hour ambulatory blood pressure and heart rate  will begin at 8am.  
 
On Day #9, the following will occur:  
• The participant  will continue with 24-hour ambulatory blood pressure 
and heart rate recorder for cardiovascular monitoring  until 4pm.  
• The participant  will also be asked to fill out several Questionnaires.  
• There will continue  to be  24-hour urine collections  until 4pm . 
9.5 Summary of Standardized Puffing Protocols  
• Electronic Cigarette ARM 1st Generation Device:  
1 puff every 30 seconds for a total of 15 puffs  
  
• Electronic Cigarette ARM 2nd/3rd Generation Devices :  
  1 puff every 30 seconds for a total of 10 puffs  
 
• Tobacco Cigarette ARM:  
1 puff every 30 seconds until the cigarette is completely smoked  
 
9.6 Product Weighing Procedures  
For the EC 1st Generation Devices, our weighing procedure was the following:  
Clinical Pharmacology of Electronic Cigarettes   IRB#  15-15992  
 32 • Pre-Outpatient Period – The CRC would label each 1st generation device 
with a sequence number using a sharpie. CRC would weigh each device 
without any product packaging.  
• Pre-standardized session – The device and/or cartridges were weighed by 
the CRC prior to the standardized session and recorded on the EC Product 
Weights Form to account for the outpatient product usage.  After this, GSH 
weighed the entire device (including the cartridge) prior to the 
standardized session and recorded this weight on the PK Product Weights Form.  This information was copied to the EC Product Weights form by the CRC, and can be found under the “Standardized Session” portion of the 
form.  
• Post -stand ardized session – GSH weighed the entire device (including 
cartridge) after to the standardized session and recorded this weight on the 
PK Product Weights Form.  This information was copied to the EC Product Weights form by the CRC, and can be found under the “Standardized Session” portion of the form . 
• Pre-distribution each inpatient study day – After  the standardized session, 
the device and/or cartridge used in the standardized session was weighed 
again to use as a baseline for ad -lib use later in the day  that did not 
included use during the standardized session .  While GSH always weighed 
the entire device for the standardized session, all other weights recorded 
during the inpatient and outpatient period were done as following: for disposable devices, the e ntire device was weighed, and for devices  with 
cartridges, only the cartridge was weighed. This weight was recorded on 
the EC Product Weights Form.  
• Post -use each inpatient study day – Each study day, the nurses went into 
the participant’s room at midnight to collect their products.  The following 
morning, the CRC weighed the device and/or cartridge on the scale in the clean utility room, and recorded this weight on the EC Product Weights Form.   
For the EC 2nd or 3rd Generation  
Clinical Pharmacology of Electronic Cigarettes   IRB#  15-15992  
 33 • Pre-Outpatient Period – The CRC would label each e -liquid vial with a 
sequence number using a sharpie. CRC would weigh each e- liquid vial 
(without the cap).  
• Pre-standardized session – The e -liquid vials that the participant used 
during the outpatient period were weighed (cap removed ) by the CRC 
prior to the standardized session, and recorded on the EC Product Weights 
Form to account for the outpatient product usage.  For e -liquid vials that 
utilize d a dropper, the residual e -liquid contained in the dropper was 
squeezed into the vial prior to weighing.  After this, GSH used some of the e-liquid to fill the device.  Then, he weighed the entire device prior to the 
standardized session and recorded this weight on the PK Product Weights 
Form.  This information was copied to the EC Product Weights form by the 
CRC, and can be found under the “Standardized Session” portion of the form 
• Post -standardized session – GSH weighed the entire device after to the 
standardized session and recorded this weight on the PK Product Weights Form.  This information was copied to the EC Product Weights form by the 
CRC, and can be found under the “Standardized Session” portion of the 
form.  
• Pre-distribution each inpatient study day – On PK days, the e -liquid vial 
used in the standardized session was weighed again to use as a baseline for ad-lib use later in the day that did not included use during the 
standardized session.  While GSH always weighed the entire device for the standardized session, all other weights recorded during the inpatient and 
outpatient period were for the e- liquid vial only.  For e -liquid vials that 
utilize a dropper, the residual e -liquid contained in the dropper was 
squeezed into the vial prior to weighing.  This weight was recorded on the 
EC Product Weights Form.  
• Post -use each inpatient stud y day – Each study day, the nurses went into 
the participant’s room at midnight to collect their products.  The following morning, the CRC weighed the e- liquid vial on the scale in the clean utility 
room, and recorded this weight on the EC Product Weights Form  to 
account for the participant’s product usage the previous day.  For e -liquid 
Clinical Pharmacology of Electronic Cigarettes   IRB#  15-15992  
 34 vials that utilize a dropper, the residual e -liquid contained in the dropper 
was squeezed into the vial prior to weighing.  
For the tobacco cigarettes, our weighing procedur e was the following:  
• Pre-Outpatient Period – The CRC would weigh 1 sample tobacco cigarette 
from a pack and record as pre weight on the “Average cigarette weight” on 
the TC Products outpatient period.  
• Post -Outpatient Period – The participant collected ci garette butts and the 
CRC counted all butts and all remaining packs/cigarettes that were brought back.  The CRC calculated the amount of tobacco burned  as: ”=(average 
cigarette weight * number of cigarettes smoked) -(average weight * number 
of cigarettes sm oked). If there was a discrepancy from what the participant 
smoked and amount of cigarette they returned, the CRC  evaluated the 
number of cigarette smoked and used that in the calculation above.   
• Note: the “Average cigarette weight” recorded on the TC Product Weights form for the outpatient period may differ in weight slightly from the “Average cigarette weight” on the TC Product Weights form during the inpatient period.  This is because when a cigarette is weighed prior to distribution at Orientation, it is  weighed on the scale at the Tobacco 
Research Center.  On the first day of the inpatient period (PK day), the 
cigarette is weighed on the scale in the Clean Utility Room of the hospital.  
This weight is used for the rest of the inpatient period.   
• Pre-standardized session – A cigarette from the participant’s pack was 
weighed by the CRC in the clean utility room prior to the standardized session, and recorded on the PK Product Weights Form and TC Product Weights Form.   
• Post -standardized session – After the standardized session, the CRC 
weighed the cigarette butt in the clean utility room and recorded this weight on the PK Product Weights Form and TC Product Weights Form.  
• Pre-distribution each inpatient study day –The weight of one cigarette 
from the participant’s pack was weighed in the clean utility room on the first inpatient study day, and recorded under the “Average cigarette weight” portion of the TC Product Weights form.  The weight of this cigarette was used  as the average cigarette weight for all other inpatient 
Clinical Pharmacology of Electronic Cigarettes   IRB#  15-15992  
 35 study days.  Each day, the number of cigarettes distributed was recorded 
on the TC Product Weights Form.   
• Post -use each inpatient study day – Each study day, the nurses went into 
the participant’s r oom at midnight to collect their products.  The following 
morning, the CRC weighed the  returned cigarette butts in the clean utility 
room and recorded this weight on the TC Product Weights Form to account for the participant’s product usage the previous da y. Under 
returned products, the “Total Weight” is equal to average cigarette weight * number of cigarette butts. “Average Weight” is equal to Total Weight/number of cigarette butts. “Tobacco Burned”=(average cigarette weight * number of cigarettes smoked) -(total weight).   In cases where the 
participant was missing a butt or returned an extra butt, the “Tobacco Burned” was calculated as: ”=(average cigarette weight * number of cigarettes smoked) -(average weight * number of cigarettes smoked).  
 
9.7 PARTICIPANT COMPENSATION  
Participants will be compensated according to Table 2 : 
Table 2  
 Screening 
Visit  Study Block #1  Study Block #2  Completion Bonus  
Compensation  $30* $600 $900 $500 
Total 
Compensation     $2,030  
*Compensation for the screening visit will be contingent upon a negative 
toxic ology drug screen (THC is okay) and a cotinine of ≥ 50 ng/mL . 
Compensation for participants who drop -out and do not make it through all 
portions of the study is described in Section  5.1.2.  
10 ADVERSE EVENTS AND PROTOCOL DEVIATIONS  
10.1 SAFETY MONITORING  
During the inpatient stay, participants  will be monitored by the CRC  and the 
nursing  staff  who will directly contact the Study P hysician in case of any 
subsequent adverse events. If the participants  experience adverse effects, the 
Study P hysician  will evaluate this with them and decide if they should be 
withdrawn from this study.  
Clinical Pharmacology of Electronic Cigarettes   IRB#  15-15992  
 36 10.2 REPORTING ADVERSE EVENTS  
Reporting of serious adverse events will follow the current requirements of the 
Institutional Rev iew Board ( IRB), with the concurrent reporting to the Nurse 
Manager at the CRC. Specifically, the following will be reported within five (5) working days of the  Principal Investigator’s (PI)  awareness, in writing:  
• All serious adverse events associated wit h  the study procedures and/or  
• Any incidents or problems involving the conduct of the study or patient participation, including problems with the recruitment and/or consent process. The PI  will provide a discussion of such events to the IRB  on an 
annu al ba sis during study renewal.  
• Any incidents or questionable adverse events are discussed at the weekly staff meetings with the PI.  
The standard adverse event grading scale will be used to report any potential adverse advents from phlebotomy, study drug, or other study procedures:  
• Grade 1 -  Mild AE:  did not require treatment  
• Grade 2 -  Moderate AE: resolved with treatment  
• Grade 3 -  Severe AE: resulted in inability to carry on normal activities and 
required profession medical attention  
• Grade 4 -  Life -threatening  or disabling AE  
• Grade 5 -  Fatal AE  
The supervising Study P hysician will be notified of all G rades 2 through 5 AEs. 
Additionally, the PI  will be notified of all grades 4  and 5 AEs. Grades 3 through 5 
AEs will be reported to the CCRC and the IRB . Grades 4 and 5 will be reported 
within 24 hours. Grade 3 will be reported within 20 days. Grade 2 will be included in the yearly progress report. Grade 1 will not be reported.  
10.3 PROTOCOL DEVIATIONS & VIOLATIONS  
Protocol de viations are  defined as an event that deviates from t he defined study 
protocol, but do es not pose any risk to t he participant or  harm to the qu ality of 
the s tudy data. For example, a follow-up ca ll may be condu cted outs ide of the 
stipulated wind ow, or  a section of  questions on a q uestionnai re may be missed 
due to a m istake in b ranching. Deviations wi ll be r ecorded on a  protocol 
deviation she et and  reviewed and signed by the PI. 
 
Protocol violations are  events t hat deviate from t he defined stu dy protocol, but 
put the p articipant at r isk and/or  cause harm to the stu dy data. Pr otocol 
Clinical Pharmacology of Electronic Cigarettes   IRB#  15-15992  
 37 violations w ill be recorded on a  protocol violation sheet, re viewed and signed by 
the PI and re ported to t he IRB. 
11 DATA COLLECTION AND MANAGEMENT  
11.1 DATA COLLECTION FORMS  
All of the following measures will be collected.  
Screening Process:  
• UCSF Tobacco Research Email Screen  5/26/2015- 2/23/18  
• E-Cigarette R01 & Flavors Study Screen  (04/01/2015- 05/26/2015)  
In-Person Screening Visit :  
• MILCOM 
• Screening Packet  
Inpatient Study Visits : 
• Day 5 , Block 1 & 2 :  
o Outpatient Withdrawal Form  
o Questionnair e of Smoking Urges (QSU)  or  modified for E -Cigarettes  
o Cigarette Evaluation Scale (mCES) or modified for E -Cigarettes  
o Positive and Negative Affect Scale ( PANAS )  
o Minnesota Behavioral Scale (MNWS)  
• Day 6 , Block 1 & 2 :  
o Questionnaire of Smoking Urges (QSU)  or  modified for E -Cigarettes  
o Cigarette Evaluation Scale (mCES) or modified for E -Cigarettes  
o Positive and Negative Affect Scale  (PANAS )  
o Minnesota Behavioral Scale (MNWS)  
• Day 7 , Block 1 & 2 :  
o Questionnaire of Smoking Urges (QSU)  or  mod ified for E -Cigarettes  
o Cigarette Evaluation Scale (mCES) or modified for E -Cigarettes  
o Positive and Negative Affect Scale  (PANAS )  
o Minnesota Behavioral Scale (MNWS)  
• Day 8 , Block 2 :  
o Questionnaire of Smoking Urges (QSU)  or  modified for E -Cigarettes  
o Positive  and Negative Affect Scale  (PANAS )  
o Minnesota Behavioral Scale (MNWS)  
• Day 9 , Block 2 : 
Clinical Pharmacology of Electronic Cigarettes   IRB#  15-15992  
 38 o Questionnaire of Smoking Urges (QSU)  or  modified for E -Cigarettes  
o Positive and Negative Affect Scale  (PANAS )  
o Minnesota Behavioral Scale (MNWS)  
o End of Study Questionnaire  
Information on how data is stored, processed and analyzed can be found in the 
Data Safety and Monitoring Plan.  
12 DUTIES AND RESPONSIBILITIES OF STAFF  
12.1 PRINCIPAL INVESTIGATOR  
The Principal Investigator is responsible for study design and oversight of implementation, data analysis, and manuscript preparation.  
12.2 CO-PRINCIPAL INVESTIGATOR S 
The Co -Principal I nvestigator s are  responsible for study design and oversight of 
implementation, data analysis, and manuscript preparation, with the assistan ce 
of the Principal Investigator.  
12.3 STUDY PHYSICIAN 
The Study Physician is responsible for medical study chart review and eligibility 
determinatio n, medical history and physical examination at SFGH admissions, 
and other medically related expertise.  
12.4 PROJECT M ANAGER  
The Project Manager is responsible for overall functioning of study coordination 
with IRB  protocols; monitoring of study budget and coordination with 
departmental administrative personnel; supervision of research associates; management of clinic fac ilities.  
12.5 CLINICAL RESEARCH COORDINATOR  
The CRC will oversee study logistics including consenting  and screening  
participants, conducting study visit procedures, coordinating inpatient admissions  and procedures  with nursing  staff  at the research ward , coordinati ng 
specimen testing with laboratory, overs eeing participant  reimbursement, 
maintaining study charts and data entry.  
 
 
Clinical Pharmacology of Electronic Cigarettes   IRB#  15-15992  
 39  
  
 
   
 
  
 
APPENDIX A: DATABASE GUIDE  
 
Schedule of Assessments  
The Schedule of Assessments is a list detailing the various specimens, forms, and 
questionnaires that are taken and administered throughout the study on any given 
study visit/study day.  Additionally, this form lists the number of samples taken, the 
analys is type for each specimen, the sample labels before and after processing, and the 
number of aliquots post -sample processing.  
• Location: t- Drive  
• Folder: 6885 Crossover E -Cigarettes  
• Sub- folder 1: Databases  
• Subfolder 2: Schedule of Assessments  
• name “Updated S chedule of Assessments 3.9.18”  
Screening Visit   
1. Screening Log  
Clinical Pharmacology of Electronic Cigarettes   IRB#  15-15992  
 40 The Screening Log is a list of all participants who came into the 20th street 
Tobacco Research Center for a screening visit for the Crossover study.  This log 
details information about each participant as well as the outcome of the visit.  Specifically, the Screening Log contains the following information: participant’s 
name , date of screening visit, RedCap ID from the RedCap pre- screening email 
survey, study ID number, toxicology and pregnancy screening results, eligibility 
status and reason, ethnicity, race, sex, 5B status (including whether or not the 
participant was a no -show)and 5B start and end date.  
• Location: t- Drive  
• Folder: 6885 Crossover E -Cigarettes  
• Sub-folder  1: Databases  
• Subfolder 2: Screening  
• name “#6685 Participant Log & Tallies”  
• Password: 6885enr  
2. Saliva Cotinine Screening Log  
The Saliva Screening Log is a list of the cotinine values for participants who came 
in for a Crossover screening visit.   
• Location: s -Drive  
• Folder: Clinical Research  
• Sub- folder 1: Screening Log  
• Subfolder 2: E -Cigarette Crossover Study  
• name “ ECigarette Crossover Saliva Cotinine Screening  Log ”  
3. Eligible Participant’s Log (only participants deemed eligible at screening)  
The Eligible Participant’s Log is a list of all participants deemed eligible to 
participate in the Crossover study after their screening visit.  This log contains 
the follow ing information: participant’s name, study ID, product assignment 
number, starting product, MRN number, 5B admission and discharge date, and 
notes regarding withdrawals, no- shows and early discharges.   Overall, we had 
54 eligible participants, and 36 comp leted participa nts. 
• Location: t- Drive  
• Folder: 6885 Crossover E -Cigarettes  
• Sub-folder: Databases  
• name “#6685 Eligible Participants Log”   
Clinical Pharmacology of Electronic Cigarettes   IRB#  15-15992  
 41 4. E-Cigarette Crossover Database  
The data collected at the screening visit is located on RedCap under the project 
titled E -Cigarette Crossover Database.  This project includes the following forms: 
Participant Summary Form, Screening Eligibility Checklist, Screening Packet, 
Physiological Assessment, NDSS, CES -D, and Wisconsin Inventory of Smoking 
Dependence Motives.  
• Location:  https://redcap.ucsf.edu/redcap_v8.1.7/index.php?pid=10780  
5. Product Photo Database  
The product photos for each participant who came in for a screening visit are 
located on the Product  Photos Database.  
a. Location: t- Drive  
b. Folder: 6885 Crossover E -Cigarettes  
c. Sub-folder: Study Coordinator Files  
d. folder name “Product Photos”  
Full Study Participant Data  
1. Inpatient Caffeine Log  
The Inpatient Caffeine Log details caffeine intake for participants during their inpatient study days.  
a. Location: t- Drive  
b. Folder: 6885 Crossover E -Cigarettes  
c. Sub-folder: Databases  
d. name “#6685 Participant Caffeine Intake”  
2. E-Cigarette Device Summary  
The E -Cigarette Device Summary is a list of the device names, g eneration and e -
liquid constituents that each participant used during the study.  
a. Location: t- Drive  
b. Folder: 6885 Crossover E -Cigarettes  
c. Sub-folder: Databases  
d. name “#6885 Crossover E -Cigarette Devices Summary”  
3. Crossover Specimen Log  
The Crossover Specimen L og is a file is a database used to track all of the 
specimens collected during participants’ orientation visit and inpatient study days.  This log contains the following information: specimen type, dates and 
Clinical Pharmacology of Electronic Cigarettes   IRB#  15-15992  
 42 times of specimen collection, date of lab sample  transfers, and volume/pH of 
urine specimens.  
a. Location: t- Drive  
b. Folder: Clinical Research Operations  
c. Sub-folder  1: Lab Processing and Reference  
d. Sub-folder  2: Specimen Logs  
e. name “6885 6885 E -Cig XO Specimen Log” 
4. Urine Catecholamine Summary  
The Urine Catecho lamine Summary contains the catecholamine data from each 
participant, including: creatinine, epinephrine, and dopamine per volume, per 24 
hours, and ratio to CRT.  
• Location: t- Drive  
• Folder: 6885 Crossover E -Cigarettes  
• Sub-folder 1: Databases  
• Sub-folder 2: Urine Catecholamines  
• name“#6885 Urine Catecholamine  Summary”  
• Information is downloaded from ARUP Labs using the login information 
below, then saved in the Urine Catecholamine Summary excel file  
i. Website: https://www.aruplab.com/ii/login.jsp   
ii. Username: ucsftobacco  
iii. Password: Tobacco1!  
5. Product diaries (for participants who used TimeJot app) (source data)  
The product diaries database is where the diaries are saved for participants that used the Time Jot app.  All other diary entries can be found as the paper version 
in the participant’s binder, or on RedCap.  
a. Location: t- Drive  
b. Folder: 6885 Crossover E -Cigarettes  
c. Sub- folder 1: Databases  
d. Sub- folder 2: Product Diaries  
6. Cardiovascular Monitoring (source data)  The C ardiovascular Monitoring database is where the CV data can be found for 
all participants.   
a. Location: t- Drive  
b. Folder: 6885 Crossover E -Cigarettes  
Clinical Pharmacology of Electronic Cigarettes   IRB#  15-15992  
 43 c. Sub- folder 1: Databases  
d. Sub- folder 2: 24 hour Cardiovascular Monitoring  
7. E-Cigarette Crossover Database  
The E -Cigarette Crossover Database is a database in RedCap where most study 
data has been entered.  This database includes the following forms: Product 
Accountability Form, Product Weight Form, product diaries, inpatient participant weights, Pre -Standardized Que stionnaire, Post -Standardized 
Questionnaire, 2 -Hour Abstinence Questionnaire, 4 -Hour Abstinence 
Questionnaire, 8am Ad -Lib Questionnaire, 8:15 am Ad -Lib Questionnaire, 12pm 
Ad-Lib Questionnaire, 4pm Ad -Lib Questionnaire, 8pm Ad -Lib Questionnaire, 
8am Abstin ence Questionnaire, 12pm Abstinence Questionnaire, 4pm Abstinence 
Questionnaire, 8pm Abstinence Questionnaire, 24 -hour cardiovascular 
monitoring data, 48 -hour Product Use Form, End of Study Questionnaire, 
Withdrawal Symptoms Questionnaire, and adverse even t reports.  
• Location: https://redcap.ucsf.edu/redcap_v8.1.7/index.php?pid=10780
 
 
8. 6885 CV Data (cleaned data)  
The 6885 CV Data is a project in RedCap that includes the CV data from all 
Crossover participants.  Individual data points on this project may differ slightly from those on the 24 -hour cardiovascular monitoring form on the E -Cigarette 
Crossover Database.   The cardiovascular data on the E -Cigarette Crossover 
Database was ente red into RedCap manually, whereas the data on this project 
was imported directly into RedCap from the source.  
 
9. 6885 Diary Data (cleaned data)  The 6885 Diary Data is a project in RedCap that includes the diary data from Crossover participants.  Individual data points on this project may differ slightly from those on the product diary form on the E -Cigarette Crossover Database.   
The product diary data on the E -Cigarette Crossover Database was entered into 
RedCap manually, whereas some of the data on this pr oject was imported 
directly into RedCap from the source.  
   
Clinical Pharmacology of Electronic Cigarettes   IRB#  15-15992  
 44  
   
APPENDIX B: STUDY POST -MORTEM  
• Eating times on nurses flow sheets . Indicate exactly when it is okay for them to 
eat, around study procedures.  
• Get 6mL of e -liquid for Gideon ahead of time, prio r to the PK day for e -cig 
• The study procedures need to be changed so that parti cipants  do not get the $30 
bonus check if they vaped the morning of PK day, rather than just having the 
CO<5 requirement.  
o $30 gift card that morning if they abstain  
o We will do Expired CO  
o We will do “bogus pipeline” for vaping  
o We will tell them that we are checking for both  
• MD orders and nurses flowsheets should specify that single stick blood draws 
using a butterfly needle are okay at the participant’s request.  Some participant’s 
preferred this and Delia had to write this in the orders each time.  
• Specify the pre -blood draw  on the nurses flowsheets as its own discrete step on 
PK days.  
• Have the nurses check on the participant’s ABPM every 4 hours or so (put in 
nurses flowsheets).  Instruct the nurses to press the manual button if there are 
repeated errors.  
• Get rid of the note page on each inpatient questionnaire.  
o CRC notes should just be recorded on the session log.  
• Get rid of the volume portion on the EC product weights form (unless we start using mathematical formula using starting volume, initial wt. and final wt. to calculate exact volume used).  
• In the nurses flowsheet on the mornings when the ABPM will be placed, write in something along the lines of “Do NOT let the participant shower after 7:30 AM).   
• Have the nurses place the cuff instead of the CRC, but CRC can do t he first 
reading or we train them to turn on and do it.  
 
 